Siemens Healthineers has acquired NEO New Oncology of Cologne, Germany, marking the company's entry into molecular testing-related services for oncology and genomics.
The deal, which was completed in March, offers Siemens a presence in genomic testing based on next-generation sequencing (NGS) technology and expands its capabilities in prediction medicine and companion diagnostics, according to the vendor. In addition, the purchase establishes a business in the field of molecular services; Siemens said it plans to provide testing and enablement services to physicians, hospitals, and laboratories.
NEO New Oncology's NEO1 cancer genome diagnostic platform will provide pathologists and oncologists with molecular information to help select targeted cancer therapies, according to the vendor. It's also developing molecular profiling assays based on NGS technology for both specimens and body liquids, Siemens said.
